Journal
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Volume 31, Issue 12, Pages 2273-2276Publisher
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.31.2273
Keywords
oleuropein; Toxoplasma gondii; Fraxinus rhynchophylla; toxoplasmosis
Categories
Funding
- Korea Foundation for International Cooperation of Science & Technology (KICOS) [2007-00208]
- Ministry of Commerce, Industry and Energy (MOCIE), Korea [RTI05-03-02]
- Korea Institute of Industrial Technology(KITECH) [RTI05-03-02] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- Ministry of Education, Science & Technology (MoST), Republic of Korea [2007-00208] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii, with very few therapeutic treatment Options. Typically, the choices for treatment are pyrimethamine and sulfadiazine, however their utility is limited because of drug toxicity and serious side effects. For these reasons, new drugs with lower toxicity are urgently needed. In this study, the compound oleuropein isolated from Fraxinus rhychophylla showed anti-T. gondii effects in vitro and in vivo. In Madin-Darby bovine kidney cells, the selectivity of oleuropein was 8.9, which was higher than sulfadiazine and pyrimethamine (3.8 and 2.5, respectively). In infected mice, the inhibition ratio of T. gondii in the peritoneal cavity was 55.4%, compared to the negative control group after treatment with 300 mg/kg oleuropein. In addition, inhibitory effects on granuloma, apoptosis, necrosis and cyst-formation were shown in sections of spleen and liver. Oleuropein is therefore a potentially useful anti-T. gondii candidate for clinical application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available